Prof. Dr. Luitpold Distel



Organisationseinheit


Strahlenklinik
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören


Publikationen (Download BibTeX)

Go to first page Go to previous page 1 von 8 Go to next page Go to last page

Jost, T., Hecht, M., Fietkau, R., & Distel, L. (2019). Influence of the Kinase Inhibitor Palbociclib on the Migration of malignant and non-malignant Cells under Irradiation. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S171-S171). Munster, DE: HEIDELBERG: SPRINGER HEIDELBERG.
Seeberg, J., Loibl, M., Moser, F., Schwegler, M., Büttner-Herold, M., Daniel, C.,... Distel, L. (2019). Non-professional phagocytosis: a general feature of normal tissue cells. Scientific Reports, 9(1). https://dx.doi.org/10.1038/s41598-019-48370-3
Schuster, B., Schenker, H., Fietkau, R., & Distel, L. (2019). Patients with Lupus Erythematosus often have increased Radiosensitivity. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S81-S82). Munster, DE: HEIDELBERG: SPRINGER HEIDELBERG.
Echarti, A., Hecht, M., Fietkau, R., & Distel, L. (2019). Prognostic Importance of the CD8-based Immune Status Inflamed, immune-Excluded, and immune Desert in Head and Neck Cancer Patients can be further subdivided by regulatory T Cells. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S44-S44). Munster, DE: HEIDELBERG: SPRINGER HEIDELBERG.
Schenker, H., Schuster, B., Fietkau, R., & Distel, L. (2019). Scleroderma and Radiation Sensitivity. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S97-S97). Munster, DE: HEIDELBERG: SPRINGER HEIDELBERG.
Koca, S., Distel, L., Lubgan, D., Weissmann, T., Lambrecht, U., Lang-Welzenbach, M.,... Putz, F. (2019). Time course of pain response and toxicity after whole-nerve-encompassing LINAC-based stereotactic radiosurgery for trigeminal neuralgia—a prospective observational study. Strahlentherapie und Onkologie, 195(8), 745-755. https://dx.doi.org/10.1007/s00066-019-01450-9
Stritzelberger, J., Distel, L., Buslei, R., Fietkau, R., & Putz, F. (2018). Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clinical & Translational Oncology, 20(4), 508-516. https://dx.doi.org/10.1007/s12094-017-1743-x
Klein, S., Wegmann, M., Distel, L., Neuhuber, W., & Kryschi, C. (2018). APTES-Terminated ultrasmall and iron-doped silicon nanoparticles as X-Ray dose enhancer for radiation therapy. Biochemical and Biophysical Research Communications, 498(4), 855-861. https://dx.doi.org/10.1016/j.bbrc.2018.03.070
Hoffmann, C., Distel, L., Knippen, S., Gryc, T., Schmidt, M., Fietkau, R., & Putz, F. (2018). Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance. Neuro-Oncology, 20(2), 268-278. https://dx.doi.org/10.1093/neuonc/nox150
Hecht, M., Meier, F., Zimmer, L., Polat, B., Loquai, C., Weishaupt, C.,... Heinzerling, L. (2018). Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients. British Journal of Cancer, 118(6), 785-792. https://dx.doi.org/10.1038/bjc.2017.489

Zuletzt aktualisiert 2017-15-10 um 02:01